Risk factors for early postoperative psychological problems in breast cancer patients after axillary lymph node dissection

Breast Cancer ◽  
2019 ◽  
Vol 27 (2) ◽  
pp. 284-290 ◽  
Author(s):  
Yoshiteru Akezaki ◽  
Eiji Nakata ◽  
Masato Kikuuchi ◽  
Ritsuko Tominaga ◽  
Hideaki Kurokawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Lymph Node ◽  
Cancer Patients ◽  
Axillary Lymph Node Dissection ◽  
Lymph Node Dissection ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Node Dissection

Targeted axillary lymph node dissection in breast cancer patients using I-125 microseeds for prostate cancer brachytherapy.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12601-e12601
Author(s):  
Alexander Emelyanov ◽  
Krivorotko Petr ◽  
Roman Pesotskiy ◽  
Alexander Bessonov ◽  
Viktor Gorelov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Axillary Lymph Node Dissection ◽  
Lymph Node Dissection ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Node Dissection

e12601 Background: To date, targeted axillary lymph node dissection is one of the possible methods of de-escalation of surgical aggression on the areas of regional lymph flow in breast cancer patients with confirmed metastases in the axillary lymph nodes prior to the neoadjuvant chemotherapy. There are no specialized microseeds for targeted axillary dissection. The purpose of our study was to determine the possibility of using I-125 microseed for prostate cancer brachytherapy for targeted axillary dissection. Methods: A prospective study of patients with biopsy-confirmed nodal axillary metastases with a I-125 microseed placed in the node was performed. I-125 microseed for prostate cancer brachytherapy was used to mark the axillary lymph node. After neoadjuvant therapy, patients underwent targeted axillary lymph node dissection in combination with SLNB with pathomorphological examination of marked lymph node and total axillary lymph node dissection with pathomorphological examination of over lymph nodes for FNR evaluation. Results: 45 breast cancer patients stage cT1-3N1M0 were enrolled in the study. The frequency of reaching ypN0 was 58%. Residual disease identified in 19 patients. The clipped node revealed metastases in 18 patients, resulting in an FNR of 5.26% (95% CI, to 20.6) for the clipped node. CIs for FNR were calculated using exact (Clopper-Pearson) confidence limits for the binomial proportion. Conclusions: Marking the biopsy-confirmed lymph node using a I-125 microseed prior neoadjuvant chemotherapy and performing targeted axillary lymph node dissection in combination with SLNB is a safe method for diagnosing axillary lymph nodes and allows you to abandon routine ALD for ypN0 patients. Advantages of I-125 microseed for prostate cancer brachytherapy: fixation in the lymph node without migration, the ability to use a standard gamma-probe to locate the microseed during the operation, these microseeds are registered for the treatment of cancer patients.

Breast Cancer Patients with Extra-Axillary Sentinel Nodes Only may be Spared Axillary Lymph Node Dissection

2008 ◽  
Vol 15 (11) ◽  
pp. 3239-3243 ◽  
Author(s):  
Iris M. C. van der Ploeg ◽  
Pieter J. Tanis ◽  
Renato A. Valdés Olmos ◽  
Bin B. R. Kroon ◽  
Emiel J. T. Rutgers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Axillary Lymph Node Dissection ◽  
Lymph Node Dissection ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Node Dissection ◽  
Sentinel Nodes

scholarly journals Incidence and Risk Factors of Arm Lymphedema Following Breast Cancer Treatment

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 213s-213s
Author(s):  
M. Owusu Sekyere
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Lymph Node ◽  
Cancer Patients ◽  
Axillary Lymph Node Dissection ◽  
Late Stage ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Node Dissection

Background: All breast cancer patients are at risk for developing lymphedema (LE) as a complication of breast cancer surgery and radiation. The reported incidence ranges from 5%-60%. In Ghana, 50% of women with breast cancer who come to the hospital present with late-stage breast cancer. Komfo Anokye Teaching Hospital (KATH) has no available data to support LE incidence. Aim: To determine the incidence and risk factors of lymphedema after breast cancer treatment at the oncology unit of KATH, Kumasi, Ghana between 01 January 2005 to 31 December 2008. Methods: Breast cancer and lymphedema related variables were collected from the medical records of breast cancer patients. Data were analyzed using descriptive statistics and χ2 tests. Results: Among 313 patients treated for breast cancer between 2005 and 2008, 31 (9.9%) developed lymphedema after treatment. A χ2 test showed that axillary lymph node dissection was statistically a significant risk factor of lymphedema (χ2 test value = 7.055, P = 0.008). Radiation and late stage of breast cancer diagnosis may have contributed in development of lymphedema despite having P value > 0.05. Age, BMI and hypertension were also not associated with lymphedema. Conclusion: This study provides evidence that the incidence of lymphedema was 9.9% with axillary lymph node dissection as a statistically significant risk factor of lymphedema. Implication for practice: With majority of breast cancer patients presenting with late stage disease and also undergoing axillary lymph node dissection, lymphedema will continue to be a problem in Ghana. Knowing the incidence and risk factors of lymphedema not only helps in the early detection and effective management of lymphedema but also provides base-line data for further research on lymphedema in Ghana.

Sign in / Sign up

Export Citation Format

Share Document